ChartRow logo
LLY
Eli Lilly and CompanyStock · Healthcare · S&P 500 1.3%
$1,225.73+$42.57 (+3.60%)as of market close, Aug 18, 2026
☾ After hours:$1,227.00+0.10%7:29 PM ET
CompareUNHJNJISRGABBVTMOMRK

LLY financial statements

The full income statement, balance sheet, and cash-flow statement for Eli Lilly and Company (LLY), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Shares outstanding (point-in-time)

2024-06 904.2M2024-09 905.0M2024-12 903.2M2025-03 900.6M2025-06 899.8M2025-09 898.8M2025-12 898.1M2026-03 895.9M2026-06 893.7M-1.2% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

About this data

Source: LLY's SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn't file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all LLY filings on SEC EDGAR → Not investment advice.